p_-CJ, $Y ; 6EvveEa ^xy/Ww|c,/P @BDS! s ;PrQI C$eAnx8p~ `:O+cv+QwOwc V0)t OD2`9OLOD vi Jn,64^,d #{p} ~|%6`k|k:~|A~6b8d~] |S#Su {}x(PD{ WY0)h0ZYT0Z }?F\?~?c /zUU8. J?v Jd%JI_% H} QEx ?]T z6LW( u}uWnn-n 9! ,$TV l\^v3 V]d m/jEj!{jd Rt zPF@ 7u&N+cQQN.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL. This PFS benefit was reported across all major subgroups, including the del(17p)/*mNs^8V- population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac safety profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.